The ROE as of November 2024 (TTM) for Cardiff Oncology, Inc. (CRDF) is -62.65%

According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -62.65%. This represents a change of 286.66% compared to the average of -16.20% of the last 4 quarters.

Cardiff Oncology, Inc. (CRDF) Historical ROE (quarterly & annually)

How has CRDF ROE performed in the past?

The mean historical ROE of Cardiff Oncology, Inc. over the last ten years is -132.28%. The current -62.65% ROE has changed -52.64% with respect to the historical average. Over the past ten years (40 quarters), CRDF's ROE was at its highest in in the March 2021 quarter at -4.15%. The ROE was at its lowest in in the June 2017 quarter at -229.18%.

Cardiff Oncology, Inc. (CRDF) ROE by Quarter and Year

Discovering the peaks and valleys of Cardiff Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cardiff Oncology, Inc. (CRDF) Average ROE

How has CRDF ROE performed in the past?

The current ROE of Cardiff Oncology, Inc. (CRDF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cardiff Oncology, Inc. (CRDF) ROE vs. Peers

How is CRDF’s ROE compared to its peers?

Cardiff Oncology, Inc.’s ROE is less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than PDS Biotechnology Corporation (-137.06%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Eyenovia, Inc. (-615.55%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than TransCode Therapeutics, Inc. (-597.47%), greater than Kodiak Sciences Inc. (-77.23%), greater than SELLAS Life Sciences Group, Inc. (-17349.62%), less than NLS Pharmaceutics AG (22.54%), greater than Mereo BioPharma Group plc (-63.39%), less than Aravive, Inc. (704.58%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than IN8bio, Inc. (-173.12%), greater than Cue Biopharma, Inc. (-142.93%), greater than Lantern Pharma Inc. (-46.39%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Autolus Therapeutics plc (-66.76%),

Build a custom stock screener for Cardiff Oncology, Inc. (CRDF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cardiff Oncology, Inc. (CRDF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.